We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Samuel Merrill

Samuel A Merrill MD, PhD

Instructor, Department of Medicine, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD

Dr. Merrill is a clinician scientist with laboratory investigations into mechanisms of severe anemias from altered erythrocyte survival. His research focuses on complement-mediated erythrocyte destruction, including atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and hyperhemolysis syndrome. He has a clinical interest in hemophagocytic lymphohistiocytosis (HLH), where his research focus is developing processes for timely diagnosis, quality improvement, and exploring novel therapies.

Dr. Merrill completed his MD/PhD training at Washington University in St. Louis, where his research focused on cellular pathways of vesicular transport involving the ESCRT pathway. He completed his Internal Medicine residency and Chief residency at the University of Vermont, and his Hematology fellowship and Chief fellowship at Johns Hopkins University.

Disclosures

Dr. Merrill reports no relevant disclosures.